On the other hand, a recently published SEER database analysis of 9215 newly diagnosed metastatic PCa patients, including 371 patients undergoing RP as local therapy, found a significant higher CSS rate (3 year CSS 76.5% no local treatment vs. 90.2% RP) in the group of patients undergoing RP compared to no local treatment, except patients M1c or PSA ≥ 60ng/ml [58]. The gene discussed is KLK3; the disease is posterior cortical atrophy.